746 results about "Immunoassay method" patented technology

A complex including magnetic particle bound to a metal colloid. The complex may be part of a reagent for use in a method for determining analytes. The reagent may include a binding partner specific for an analyte. The reagent may further include a first label that is distinguishable from a second label that is used to detect the analyte. The reagent is used in kits and methods for detecting analytes in samples. The methods include immunoassay methods, including method where the first label is used to calibrate the assay.

Bioelastomers are disclosed for use in methods of binding compounds including immunoassay methods, in biosensors and methods or regenerating biosensors, and in methods for targeting the delivery of a compound to a particular location within an animal subjects. In general, the bioelastomer is conjugated to a binding compound, which is in turn used to bind a compound of interest. For targeted compound delivery, the bioelastomer is conjugated to the compound to be delivered.

A method for detecting one or more target bacteria in a raw sample where: 1) bacteriophage(s) specific to each target bacterium are added to the raw sample, 2) the test sample is incubated, and 3) the test sample is tested for the presence of each phage in sufficient numbers to indicate the presence of the associated target bacteria in the raw sample. In one embodiment, each phage is initially added to the raw sample in concentrations below the detection limit of the final phage detection process. In another embodiment, the parent phages are tagged in such a way that they can be separated from the progeny phage prior to the detection process. Preferred phage detection processes are immunoassay methods utilizing antibodies that bind specifically to each phage. Antibodies can be used that bind to the protein capsid of the phage. Alternatively, the phage can by dissociated after the incubation process and the sample tested for the presence of individual capsid proteins or phage nucleic acids. The invention can be used to test target bacteria for antibiotic resistance.

Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.

This invention relates to devices and methods for performing active, multi-step molecular and biological sample preparation and diagnostic analyses employing immunochemical techniques. It relates generally to bioparticle separation, bioparticle enrichment, and electric field-mediated immunochemical detection on active electronic matrix devices utilizing AC and DC electric fields. More specifically, the invention relates to devices and methods for sample preparation / manipulation, immunoimmobilization, and immunoassays, all of which can be conducted on one or more active electronic chip devices within a single system. These manipulations are useful in a variety of applications, including, for example, detection of pathogenic bacteria and biological warfare agents, point-of-care diagnostics, food or medical product quality control assays, and other biological assays.

A chip-based capillary electrophoresis assembly including: a holder including a frame for removably receiving a chip; a capillary electrophoresis microchip dimensioned to fit onto the holder, and comprising a body and a separation channel defined in the body; and a pair of adhesive detection electrodes integrated with an electronic conductometric detection circuit, wherein the assembly is assemblable by disposing the capillary electrophoresis microchip on the holder and removably placing the adhesive electrodes on the microchip body near the separation channel. A label-free analyte conductometric detection method and a label-free capillary electrophoresis immunoassay method are also described.

Methods and apparatus for evanescent light fluoroimmunoassays are disclosed. The apparatus employs a planar waveguide with an integral semicylindrical lens, and has multi-analyte features and calibration features, along with improved evanescent field intensity. A preferred embodiment of the biosensor and assay method has patches of capture molecules, each specific for a different analyte disposed adjacently within a single reservoir. The capture molecules are immobilized to the patches on the waveguide surface by site-specific coupling of thiol groups on the capture molecules to photo-affinity crosslinkers, which in turn are coupled to the waveguide surface or to a nonspecific binding-resistant coating on the surface. The patches of different antibodies are produced by selectively irradiating a portion of the waveguide surface during the process of coupling the photo-affinity crosslinkers, the selective irradiation involving a mask, a laser light source, or the like.

The invention in particular relates to a whole-blood labeled immunoassay method for quickly collecting a target object from whole-blood through specificity binding reaction and labeling and monitoring the target object by a labeling technology, and an instant detection system. The method comprises the following steps: 1) capturing magnetic beads; 2) eluting blood; 3) labeling a detection antibody; 4) eluting the detection antibody; 5) detecting. The system comprises a microfluidic chip, a magnetic field generation device arranged above or below the microfluidic chip and a detection device, wherein the microfluidic chip comprises a microchannel, the magnetic beads arranged in the microchannel, a waste liquid outlet and an eluent storage pond; the microchannel is separated into a first reaction region, a second reaction region and a detection region in stages by a separation mechanism. The technical scheme provided by the invention has the characteristics of high sensitivity, high repeatability, simple system structure, low cost and the like, and can detect the target object from trace blood samples quickly and quantitatively.

A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels.

An immunoassay method in which blood can be measured even without pretreatment by a centrifuge etc. In the present invention, antibodies or antigens in a sample are subjected to agglutination reaction with insoluble carriers onto which antigens or antibodies specifically reacting with the antibodies or antigens in the sample have been imrobilized and the resulting agglutination mixture is determined for the change in its absorbance or in its scattered light by irradiation with light, wherein said sample is whole blood and the whole blood is forcibly lysed.

The invention discloses an application of nano-gold directly bonded with luminol in an immunoassay. The invention is characterized in that the immunoassay probe of a nano-gold directly bonded with luminol comprises antibodies which are labeled by the nano-golds directly bonded with luminol, wherein the nano-gold directly bonded with luminol are prepared through reducing chloroauric acid by the luminol at a single step; a chemiluminescence immunoassay method is based on the immunoassay probe of the nano-gold directly bonded with luminol; and a kit is used for carrying out the immunoassay method. The chemiluminescence immunoassay method of the invention has the advantages of high sensitivity (for instance, the detection limit can reach 1.0pg / mL for detecting human IgG), wide range of linearity, good repeatability, simple operation, low cost and the like, can be applied to detect multi-analyte in various samples and has key application prospect in fields, such as clinical diagnosis and cure, drug analysis, food security detection, environmental monitoring and the like.

It is an object of the present invention to provide magnetic substance-encapsulated particles which have uniform magnetism, high dispersion stability and a narrow particle size distribution, a method of producing the same, particles for immunoassay formed by using the magnetic substance-encapsulated particles and a method of immunoassay in which the magnetic substance-encapsulated particles or the particles for immunoassay are used. The present invention relates to a magnetic substance-encapsulated particle, which comprises an organic polymer material and a magnetic substance having an average particle size of 1 to 30 nm, the magnetic substance being contained within a particle in a state of being dispersed.

The invention generally relates to the field of diagnostic or prognostic assays and in particular relates to assays for the detection of antibodies in a sample comprising patient bodily fluid, wherein such antibodies are used as biological markers of a disease state or disease susceptibility. The assay is based on cross-titration of both the patient bodily fluid to be tested for the antibody and an antigen used to detect the antibody by specific binding.

The invention provides a homogeneous luminescence immunoassay method for quantitatively analyzing multiple components simultaneously and a kit used for the method. Receptor microspheres containing various different fluoresceins are adopted, and antibody molecules for capturing different biological markers to be measured are enveloped in the method; in a measuring process, the multiple biological markers in a sample to be measured are combined with the corresponding antibody molecules on the surfaces of the receptor microspheres and biotinylated antibodies in a detection system respectively to form double-antibody sandwich compositions which are respectively connected with donor microspheres labeled with streptavidin; when the donor microspheres are irradiated by exciting light, all types of the receptor microspheres send out optical signals with different wavelengths; the intensities of the light with different wavelengths are respectively detected, so that the biological markers to be measured can be accurately quantified. The kit comprises the receptor microspheres containing chemiluminescence reagents and the fluoresceins, the biotinylated antibodies and the donor microspheres containing photosensitive substances. The homogeneous luminescence immunoassay method and the kit have the beneficial effects that simultaneous and quantitative measurement on multiple components is realized, and the detection cost is reduced.

A magnetic microparticle-packing unit using centrifugal force, a microfluidic device including the same, and an immunoassay method using the microfluidic device are provided. The magnetic microparticle-packing unit includes a rotary body controllably rotating; a microfluidic channel which includes a curved portion in which the microfluidic channel first extends away from the rotation center of the rotary body and then turns toward the rotation center of the rotary body.

A method of immunoassay of H5 subtype influenza A virus by which the virus can be accurately assayed even in cases where a certain level of mutation has occurred in the H5 subtype influenza A virus, and a kit therefor, and a novel anti-H5 subtype influenza A virus monoclonal antibody which can be used for the immunoassay are disclosed. The antibody or an antigen-binding fragment thereof of the present invention undergoes antigen-antibody reaction with hemagglutinin of H5 subtype influenza A virus, and the corresponding epitope of the antibody or an antigen-binding fragment thereof is located in a region other than the receptor subdomain (excluding C-terminal region thereof consisting of 11 amino acids), which antibody or an antigen-binding fragment thereof does not have neutralizing activity against the influenza A virus.

The present invention relates to (1) A reagent for an immunoassay of a target substance existing in a free form and a bound form in a specimen, comprising a latex 1 which is immobilized with a monoclonal antibody 1 for the target substance, and a latex 2 which has a different mean particle size from the latex 1 and is immobilized with a monoclonal antibody 2 having a different recognition site for the target substance from the antibody 1, (2) An immunoassay method comprising reacting the target substance with the reagent of (1) and determining an amount of the substance based on the result of an agglutination reaction among the target substance, the latex1 and the latex2, and (3) A reagent kit comprising a reagent of (1) and a reagent containing an agglutination accelerator for an antigen-antibody reaction.

The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.

The invention relates to a homogeneous immunoassay kit, detection method and application thereof in the technical field of biology. The kit comprises a reagent I, a reagent II, a reagent III and a reagent IV, wherein the reagent I contains a first counterpart, and the first counterpart is a known antigen or a known antibody specially combined with an antigen to be detected in a sample to be detected; the reagent II contains a receptor which can react with singlet oxygen to generate a detectable signal and a second counterpart combined with the receptor; the reagent III contains a third counterpart specially combined with the first counterpart; the reagent IV contains a donor which can generate the singlet oxygen in an excitation state; the surface of the third counterpart is coated with biotin, and the surface of the donor is coated with streptavidin. By utilizing combined detection of the kit and the homogeneous immunoassay method of the antigen and the antibody, the screening difficulty of raw materials is reduced, and the detection sensitivity is promoted at the same time.

A method for detection of mycobacterium tuberculosis antigens in biological fluids provides immunoassay methods, diagnostic kits, and an immunochromatoraphic assay device for detection of Mycobacterium tuberculosis antigens in biological specimens, preferably body fluids and tissues. The preferred body fluids are blood, serum, plasma, urine, pulmonary fluid, sputum, cerebrospinal fluid, and the preferred tissue is the lung biopsy specimen. The immunoassays require two primary antibodies against RD1, RD2, or RD3 of Mycobacterium tuberculosis. At least one of the primary antibodies is attached to a solid carrier. Optional, a second antibody against an animal species producing one of the primary antibodies can be added. Either the other primary antibody or the secondary antibody is labeled with a detection agent, which can be an enzymatic marker, a fluorescent or luminescent agent, a radio active label or a color particle. The biological specimens may be used directly, concentrated or diluted for the immunoassays.

Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.

Disclosed is an electrochemiluminescence immunoassay method, using a full reaction of a Ru(bpy) marked protein-primary antibody, a biotinylated protein-secondary antibody to be tested, and a sample to be tested; addition of a Streptavidin-coated magnetic particle to form a complex comprising an antigen, an antibody, and a magnetic particle; adsorption to an electrode surface by the magnetic particle; addition of a dibutyl ethanolamine solution; testing by means of an electrochemical method. Also disclosed is a corresponding electrochemiluminescence immunoassay detection kit.

A capillary for an immunoassay is provided which comprises an insoluble layer of an oxidase formed on an inner wall surface of said capillary, said oxidase being conjugated to a first antibody, and a layer of a hydrophilic polymer formed on said insoluble layer, said hydrophilic polymer layer containing a second antibody conjugated to a peroxidase, wherein said first and second antibodies are capable of binding to the same antigen.

There are provided: a method for pretreating a sample for HCV core protein detection by an immunoassay using particles, which includes treating a sample suspected of containing hepatitis C virus (HCV) with an alkaline material-containing reagent and neutralizing the sample with an acid material-containing reagent, wherein at least one of the reagents contains a reducing agent; a reagent kit for HCV core protein detection; a method for determining the presence or absence of hepatitis C virus in a sample; and a method for immunoassay of HCV.

The invention is to devices and methods for rapid determination of analytes in liquid samples. The devices and methods incorporate a sample dilution feature and multiple immunosensors for performing a ratiometric immunoassay on a first analyte and a second analyte, for example, hemoglobin and hemoglobin A1c or albumin and glycosylated albumin. The devices are preferably capable of being used in the point-of-care diagnostic field.

The invention discloses a method for preparing polyclonal antibody against mouse nerve growth factor (NGF) and application thereof in an enzyme-linked immunoassay method. The polyclonal antibody which is prepared by using mouse submandibular gland NGF as an immunogen can be used for quantitatively detecting the mouse growth factor. Therefore, an assembled kit can determine fixed position and expression of different tissue cell nerve growth factors and detect NGF contents in different samples such as blood, cells, tissues, culture medium supernatant, and the like.

A complex including magnetic particle bound to a metal colloid. The complex may be part of a reagent for use in a method for determining analytes. The reagent may include a binding partner specific for an analyte. The reagent may further include a first label that is distinguishable from a second label that is used to detect the analyte. The reagent is used in kits and methods for detecting analytes in samples. The methods include immunoassay methods, including method where the first label is used to calibrate the assay.